These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3689631)

  • 41. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates.
    Valitalo PA; van den Anker JN; Allegaert K; de Cock RF; de Hoog M; Simons SH; Mouton JW; Knibbe CA
    J Antimicrob Chemother; 2015 Jul; 70(7):2074-7. PubMed ID: 25766737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selection of optimal prophylactic aminoglycoside dosage in cancer patients: population pharmacokinetic approaches.
    Ordovás JP; Ronchera CL; Poveda JL; Jiménez NV; López R
    J Clin Pharm Ther; 1994 Feb; 19(1):47-56. PubMed ID: 8188791
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An approach to forecast aminoglycoside-related nephrotoxicity from routinely collected clinical data.
    Kubota K; Suganuma T; Sasaki T; Ishizaki T
    Ther Drug Monit; 1988; 10(4):410-20. PubMed ID: 3201525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.
    Matthews I; Kirkpatrick C; Holford N
    Br J Clin Pharmacol; 2004 Jul; 58(1):8-19. PubMed ID: 15206987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetics of tobramycin.
    Aarons L; Vozeh S; Wenk M; Weiss P; Follath F
    Br J Clin Pharmacol; 1989 Sep; 28(3):305-14. PubMed ID: 2789924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pharmacokinetic monitoring during aminoglycoside treatment: the optimal method for individualizing the dosage of tobramycin].
    Firsov AA; Manuĭlov KK; Fomina IP; Lukomskiĭ GI; Alekseeva ME
    Antibiot Khimioter; 1989 Dec; 34(12):915-20. PubMed ID: 2629652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily versus pharmacokinetic dosing of aminoglycosides.
    Medicus-Bringa M; Ward G; Rice M
    Am J Med; 1997 Oct; 103(4):328-30. PubMed ID: 9382126
    [No Abstract]   [Full Text] [Related]  

  • 48. Aminoglycoside clearance is a good estimate of creatinine clearance in intensive care unit patients.
    Jones TE; Peter JV; Field J
    Anaesth Intensive Care; 2009 Nov; 37(6):944-52. PubMed ID: 20014601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the predictions of one- and two-compartment microcomputer programs for long-term tobramycin therapy.
    Hatton RC; Massey KL; Russell WL
    Ther Drug Monit; 1984; 6(4):432-7. PubMed ID: 6549085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis.
    Mann HJ; Fuhs DW; Awang R; Ndemo FA; Cerra FB
    Clin Pharm; 1987 Feb; 6(2):148-53. PubMed ID: 3665367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tobramycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 1997 Oct; 62(4):392-9. PubMed ID: 9357390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size.
    Crass RL; Ross BE; Derstine BA; Lichty M; Sullivan JA; Su GL; Wang SC; Pai MP
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632017
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of the use of Bayesian analysis in the optimization of gentamicin therapy from the commencement of dosing.
    Chrystyn H
    Drug Intell Clin Pharm; 1988 Jan; 22(1):49-53. PubMed ID: 3349920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carbenicillin inactivation of aminoglycosides in patients with severe renal failure.
    Weibert R; Keane W; Shapiro F
    Trans Am Soc Artif Intern Organs; 1976; 22():439-43. PubMed ID: 951863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gentamicin and tobramycin Kinetics.
    Counts GW; Blair AD; Wagner KF; Turck M
    Clin Pharmacol Ther; 1982 May; 31(5):662-8. PubMed ID: 7075115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of body weight on aminoglycoside pharmacokinetics in patients with hypoalbuminemia.
    Kale-Pradhan PB; Buckler V; Bush PW
    Am J Health Syst Pharm; 1997 Oct; 54(19):2201-3. PubMed ID: 9331441
    [No Abstract]   [Full Text] [Related]  

  • 58. Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.
    Welch LP; Leader WG; Chandler MH
    Clin Pharm; 1993 Dec; 12(12):909-13. PubMed ID: 8137608
    [No Abstract]   [Full Text] [Related]  

  • 59. Gentamicin and tobramycin dosing guidelines: an evaluation.
    Matzke GR; Burkle WS; Lucarotti RL
    Drug Intell Clin Pharm; 1983 Jun; 17(6):425-32. PubMed ID: 6861633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive performance of Sawchuk-Zaske and Bayesian dosing methods for tobramycin.
    Rodvold KA; Blum RA
    J Clin Pharmacol; 1987; 27(5):419-24. PubMed ID: 3693587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.